Bassam Dahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bassam Dahman has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Binu V. John
Division of Gastroenterology and Hepatology, VA Medical Center University of Miami Miami Florida USA
2 shared publications - Cathy J. Bradley
University of Colorado, Aurora, USA
2 shared publications - Dustin Bastaich
Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA
2 shared publications - Mahmoud Manouchehri Amoli
Department of Health Policy, School of Public Health, Virginia Commonwealth University, Richmond, VA
2 shared publications - Amy E. Leader
Sidney Kimmel Comprehensive Cancer Center—Jefferson Health, Philadelphia, PA
1 shared publication - Andres Samos
Division of Gastroenterology and Hepatology, Miami VA Medical System, Miami, Florida, USA
1 shared publication
Latest Publications
- 6 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1715-1723
Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors
Background: Socioenvironmental deprivation and discrimination are associated with poorer cancer outcomes, yet their combined impact remains understudied. This study examines the independent and combined impact of these factors on cancer-related outcomes. Methods: Survey data (2018-2020) from 7977 participants across 6 National Cancer Institute–designated cancer centers assessed perceived discrimination (PD), area-level deprivation, lifestyle factors (smoking and obesity), and self-reported breast and colorectal cancer screening behaviors. Multivariate and multilevel logistic regression models estimated associations and the interclass correlation (ICC) quantified variation attributable to area-level factors. Results: High PD was associated with 2.28 times higher odds of current smoking (95% CI = 1.71 to 3.05) and 1.33 times higher odds of obesity (95% CI = 1.03 to 1.72), compared with those with low PD. Living in socially deprived areas increased the odds of smoking by 1.51 (95% CI = 1.20 to 1.89), relative to socially privileged areas. ICC estimates that 4% of the variation in the association between high PD on smoking, and 2% of the variation between medium PD and obesity, were attributable to area-level factors. Neither PD nor neighborhood disadvantage were significantly associated with being up-to-date on cancer screenings. Conclusions: PD and neighborhood deprivation independently increase risk of smoking and obesity, both cancer risk factors, but were not significantly associated with screening behaviors. Area-level factors explain modest variation in these associations. Impact: Findings highlight the importance of integrating both social experience (PD) and structural conditions (neighborhood deprivation) in cancer prevention research. For practice and policy, results underscore the need for multilevel strategies and targeted prevention efforts to reduce behavioral cancer risk.
- 6 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1715-1723
Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors
Background: Socioenvironmental deprivation and discrimination are associated with poorer cancer outcomes, yet their combined impact remains understudied. This study examines the independent and combined impact of these factors on cancer-related outcomes. Methods: Survey data (2018-2020) from 7977 participants across 6 National Cancer Institute–designated cancer centers assessed perceived discrimination (PD), area-level deprivation, lifestyle factors (smoking and obesity), and self-reported breast and colorectal cancer screening behaviors. Multivariate and multilevel logistic regression models estimated associations and the interclass correlation (ICC) quantified variation attributable to area-level factors. Results: High PD was associated with 2.28 times higher odds of current smoking (95% CI = 1.71 to 3.05) and 1.33 times higher odds of obesity (95% CI = 1.03 to 1.72), compared with those with low PD. Living in socially deprived areas increased the odds of smoking by 1.51 (95% CI = 1.20 to 1.89), relative to socially privileged areas. ICC estimates that 4% of the variation in the association between high PD on smoking, and 2% of the variation between medium PD and obesity, were attributable to area-level factors. Neither PD nor neighborhood disadvantage were significantly associated with being up-to-date on cancer screenings. Conclusions: PD and neighborhood deprivation independently increase risk of smoking and obesity, both cancer risk factors, but were not significantly associated with screening behaviors. Area-level factors explain modest variation in these associations. Impact: Findings highlight the importance of integrating both social experience (PD) and structural conditions (neighborhood deprivation) in cancer prevention research. For practice and policy, results underscore the need for multilevel strategies and targeted prevention efforts to reduce behavioral cancer risk.
- Open Access
- 1 December 2025
- Published by Wiley in The Prostate
- Vol. 86 (4) , 505-507
Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
- 1 December 2025
- Published by Wiley in The Prostate
- Vol. 86 (4) , 505-507
Open AccessBeyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
- Open Access
- 23 July 2025
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 31 (5) , e70217
MIPS Under Scrutiny: Exploring the Association Between Providers With Fraudulent Practices and Quality Metrics Within MACRA's Framework
Importance: Identifying how fraudulent practices affect quality performance metrics is crucial for enhancing healthcare delivery and maintaining the integrity of the Medicare system.Objective: To examine the association between fraud and abuse perpetrator providers (FAPs) and their performance on quality metrics within the Merit‐Based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act (MACRA).Design: A retrospective observational study using exact matching and propensity score matching to balance comparison groups.Setting: Analysis of Medicare Quality Payment Program (QPP) data from 2017 to 2021.Participants: A total of 12,364 physician‐year observations, including 1300 provider‐year level FAPs identified between 2020 and 2023 and 11,064 matched non‐FAPs.Exposures: Provider status as fraud and abuse perpetrators based on inclusion in the List of Excluded Individuals and Entities from the Office of Inspector General.Main Outcomes and Measures: MIPS scores across key categories: Final score, Quality score, Promoting Interoperability (PI) score, Improvement Activities (IA) score, and Cost score.Results: FAPs scored significantly lower than non‐FAPs in Final score, Quality score, PI score, and IA score (all p < 0.05). The negative impact of FAP status was more pronounced among individual practitioners, while FAPs participating in Advanced Alternative Payment Models exhibited higher scores on certain metrics. No significant differences were observed in Cost scores between FAPs and non‐FAPs.Conclusions and Relevance: Fraudulent practices are associated with lower performance on quality‐related metrics under MACRA's MIPS framework, particularly among individual practitioners. While lower quality scores align with expectations for providers committing fraud, the absence of significant differences in Cost scores highlights potential shortcomings in the MIPS scoring system, suggesting that cost metrics may not be sufficiently sensitive to fraudulent practices. These findings underscore the need for continuous refinement of both quality and cost measures to enhance the integrity and effectiveness of healthcare delivery.
- 23 July 2025
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 31 (5) , e70217
Open AccessMIPS Under Scrutiny: Exploring the Association Between Providers With Fraudulent Practices and Quality Metrics Within MACRA's Framework
Importance: Identifying how fraudulent practices affect quality performance metrics is crucial for enhancing healthcare delivery and maintaining the integrity of the Medicare system.Objective: To examine the association between fraud and abuse perpetrator providers (FAPs) and their performance on quality metrics within the Merit‐Based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act (MACRA).Design: A retrospective observational study using exact matching and propensity score matching to balance comparison groups.Setting: Analysis of Medicare Quality Payment Program (QPP) data from 2017 to 2021.Participants: A total of 12,364 physician‐year observations, including 1300 provider‐year level FAPs identified between 2020 and 2023 and 11,064 matched non‐FAPs.Exposures: Provider status as fraud and abuse perpetrators based on inclusion in the List of Excluded Individuals and Entities from the Office of Inspector General.Main Outcomes and Measures: MIPS scores across key categories: Final score, Quality score, Promoting Interoperability (PI) score, Improvement Activities (IA) score, and Cost score.Results: FAPs scored significantly lower than non‐FAPs in Final score, Quality score, PI score, and IA score (all p < 0.05). The negative impact of FAP status was more pronounced among individual practitioners, while FAPs participating in Advanced Alternative Payment Models exhibited higher scores on certain metrics. No significant differences were observed in Cost scores between FAPs and non‐FAPs.Conclusions and Relevance: Fraudulent practices are associated with lower performance on quality‐related metrics under MACRA's MIPS framework, particularly among individual practitioners. While lower quality scores align with expectations for providers committing fraud, the absence of significant differences in Cost scores highlights potential shortcomings in the MIPS scoring system, suggesting that cost metrics may not be sufficiently sensitive to fraudulent practices. These findings underscore the need for continuous refinement of both quality and cost measures to enhance the integrity and effectiveness of healthcare delivery.
- 10 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (3) , 697-709
Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study
INTRODUCTION: Anecdotal observations report a decrease in craving for alcohol among patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RA). We aimed to assess liver-related outcomes and mortality among individuals with harmful alcohol use who received GLP-1 RAs. METHODS: We emulated a target trial using the electronic health records of US Veterans with positive alcohol use disorders-concise score (AUDIT-C), comparing new initiators of GLP-1 RA between 1/3/2017 and 9/30/2024, with controls, with follow-up until outcomes or study end. Each GLP-1 RA new user with a positive AUDIT-C screen was propensity score (PS) matched 1:1 with a patient not on a GLP-1 RA. The primary outcomes were the time to a composite outcome of decompensation, hepatocellular carcinoma, liver-related death, and all-cause mortality. The secondary outcome was the proportion of patients with positive AUDIT-C scores. RESULTS: We matched 8,040 patients with positive AUDIT-C initiated on GLP-1 RA with 8,040 noninitiators. GLP-1 RA use was associated with a lower risk of composite liver-related outcomes (adjusted hazard ratio [aHR], 0.70; 95% confidence interval [CI] 0.56–0.87) and death (aHR 0.43, 95% CI 0.37–0.49). Among semaglutide users, a 1 mg/wk dose increase was associated with a reduced risk of composite liver-related outcomes (aHR 0.50, 95% CI 0.29–0.88) and death (aHR 0.33, 95% CI 0.19–0.58). GLP-1 RA use was also associated with lower odds of positive AUDIT-C during follow-up (adjusted Odds ratio 0.75, 95% CI 0.68–0.82). DISCUSSION: In this observational target trial emulation study, GLP-1 RA use was associated with a lower risk of liver outcomes, death, and harmful alcohol use.
- 10 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (3) , 697-709
Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study
INTRODUCTION: Anecdotal observations report a decrease in craving for alcohol among patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RA). We aimed to assess liver-related outcomes and mortality among individuals with harmful alcohol use who received GLP-1 RAs. METHODS: We emulated a target trial using the electronic health records of US Veterans with positive alcohol use disorders-concise score (AUDIT-C), comparing new initiators of GLP-1 RA between 1/3/2017 and 9/30/2024, with controls, with follow-up until outcomes or study end. Each GLP-1 RA new user with a positive AUDIT-C screen was propensity score (PS) matched 1:1 with a patient not on a GLP-1 RA. The primary outcomes were the time to a composite outcome of decompensation, hepatocellular carcinoma, liver-related death, and all-cause mortality. The secondary outcome was the proportion of patients with positive AUDIT-C scores. RESULTS: We matched 8,040 patients with positive AUDIT-C initiated on GLP-1 RA with 8,040 noninitiators. GLP-1 RA use was associated with a lower risk of composite liver-related outcomes (adjusted hazard ratio [aHR], 0.70; 95% confidence interval [CI] 0.56–0.87) and death (aHR 0.43, 95% CI 0.37–0.49). Among semaglutide users, a 1 mg/wk dose increase was associated with a reduced risk of composite liver-related outcomes (aHR 0.50, 95% CI 0.29–0.88) and death (aHR 0.33, 95% CI 0.19–0.58). GLP-1 RA use was also associated with lower odds of positive AUDIT-C during follow-up (adjusted Odds ratio 0.75, 95% CI 0.68–0.82). DISCUSSION: In this observational target trial emulation study, GLP-1 RA use was associated with a lower risk of liver outcomes, death, and harmful alcohol use.
- Open Access
- 1 May 2025
- Published by Wiley in Health Services Research
- Vol. 60 (5) , e14631
Navigating New Waters: How Did MACRA 2015 Transform Practices Among Medicare Part B Physicians?
Objectives: To assess whether physicians participating in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) exhibit different billing behaviors and practice patterns compared to non‐participating physicians after MACRA implementation.Study Setting and Design: A quasi‐experimental staggered difference‐in‐difference design was used to compare pre‐and post‐MACRA changes among participants and non‐participants from 2013 to 2021. Primary outcomes included annual submitted charges, annual Medicare payments, and charge‐to‐payment ratios. Secondary outcomes were average charges and payments per beneficiary, total services, and the number of beneficiaries served.Data Sources and Analytic Sample: The study analyzed secondary data from Centers for Medicare & Medicaid Services (CMS) Medicare Fee‐For‐Service Provider Utilization and Payment Data (2013–2021), providing outcome measures and control variables; Quality Payment Program (QPP) Experience Reports (2017–2021), the National Plan and Provider Enumeration System, and Medicare Geographic Variation Public Use File. The analytic sample included 4,924,118 physician‐year observations (749,129 unique physicians), with 50.2% participating in MACRA.Principal Findings: MACRA participation was associated with significant annual increases of $36,677 (95% CI: 28,918, 44,436) in total submitted charges and $9164 (95% CI: 7288, 11,041) in total Medicare payments compared to non‐participation. However, these increases appeared primarily driven by a substantial increase in the total number of Medicare beneficiaries served per physician (29.77 beneficiaries; 95% CI: 20.75, 32.79) rather than by increases in spending per beneficiary, which were modest (average payment increase per beneficiary of $2.10; 95% CI: 0.22, 3.97). The charge‐to‐payment ratio decreased by 0.04 percentage points (95% CI: −0.08, −0.00) among MACRA participants, suggesting potential improvements in billing efficiency.Conclusions: MACRA participation is associated with increased billing and payment among Medicare Part B physicians, primarily driven by physicians treating a greater number of Medicare beneficiaries. However, modest changes in per‐beneficiary spending suggest limited changes in care intensity. Further research is needed to explore factors influencing patient volumes and payer mix under MACRA.
- 1 May 2025
- Published by Wiley in Health Services Research
- Vol. 60 (5) , e14631
Open AccessNavigating New Waters: How Did MACRA 2015 Transform Practices Among Medicare Part B Physicians?
Objectives: To assess whether physicians participating in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) exhibit different billing behaviors and practice patterns compared to non‐participating physicians after MACRA implementation.Study Setting and Design: A quasi‐experimental staggered difference‐in‐difference design was used to compare pre‐and post‐MACRA changes among participants and non‐participants from 2013 to 2021. Primary outcomes included annual submitted charges, annual Medicare payments, and charge‐to‐payment ratios. Secondary outcomes were average charges and payments per beneficiary, total services, and the number of beneficiaries served.Data Sources and Analytic Sample: The study analyzed secondary data from Centers for Medicare & Medicaid Services (CMS) Medicare Fee‐For‐Service Provider Utilization and Payment Data (2013–2021), providing outcome measures and control variables; Quality Payment Program (QPP) Experience Reports (2017–2021), the National Plan and Provider Enumeration System, and Medicare Geographic Variation Public Use File. The analytic sample included 4,924,118 physician‐year observations (749,129 unique physicians), with 50.2% participating in MACRA.Principal Findings: MACRA participation was associated with significant annual increases of $36,677 (95% CI: 28,918, 44,436) in total submitted charges and $9164 (95% CI: 7288, 11,041) in total Medicare payments compared to non‐participation. However, these increases appeared primarily driven by a substantial increase in the total number of Medicare beneficiaries served per physician (29.77 beneficiaries; 95% CI: 20.75, 32.79) rather than by increases in spending per beneficiary, which were modest (average payment increase per beneficiary of $2.10; 95% CI: 0.22, 3.97). The charge‐to‐payment ratio decreased by 0.04 percentage points (95% CI: −0.08, −0.00) among MACRA participants, suggesting potential improvements in billing efficiency.Conclusions: MACRA participation is associated with increased billing and payment among Medicare Part B physicians, primarily driven by physicians treating a greater number of Medicare beneficiaries. However, modest changes in per‐beneficiary spending suggest limited changes in care intensity. Further research is needed to explore factors influencing patient volumes and payer mix under MACRA.
- 16 January 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (11) , 2583-2591
Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort
INTRODUCTION: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as clinical entities; tools to identify patients from electronic health records (EHRs) to perform large outcome studies are lacking. METHODS: In this retrospective study of participants from the Veterans Analysis of Liver Disease cohort assembled from 1/1/2013 to 12/31/2022, a rule-based natural language processing (NLP) algorithm searched EHRs for imaging evidence of hepatic steatosis. This was combined with identification of cardiometabolic risk factors and harmful alcohol use. Algorithm-derived diagnoses of MASLD, MetALD, alcohol-associated steatotic liver disease (ALD), and no steatotic liver disease (SLD) were validated using a blinded review of randomly selected charts. RESULTS: Among 817,657 eligible veterans, SLD was present in over half (n = 438,209, 53.5%), including MASLD in 299,259 (36.5%), 99,163 with MetALD (12.1%), and 38,552 (4.7%) with ALD. The NLP algorithm had a high correlation with steatosis on chart review, with a κ of 0.86 (95% CI 0.82–0.90), sensitivity of 0.96, and specificity of 0.90. Classification of MASLD, MetALD, ALD, and no SLD by the algorithm also showed high correlation with chart review, with a κ of 0.87 (95% CI 0.82–0.91). This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using I nternational Classification of D iseases-9/10 codes. DISCUSSION: An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration.
- 16 January 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (11) , 2583-2591
Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort
INTRODUCTION: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as clinical entities; tools to identify patients from electronic health records (EHRs) to perform large outcome studies are lacking. METHODS: In this retrospective study of participants from the Veterans Analysis of Liver Disease cohort assembled from 1/1/2013 to 12/31/2022, a rule-based natural language processing (NLP) algorithm searched EHRs for imaging evidence of hepatic steatosis. This was combined with identification of cardiometabolic risk factors and harmful alcohol use. Algorithm-derived diagnoses of MASLD, MetALD, alcohol-associated steatotic liver disease (ALD), and no steatotic liver disease (SLD) were validated using a blinded review of randomly selected charts. RESULTS: Among 817,657 eligible veterans, SLD was present in over half (n = 438,209, 53.5%), including MASLD in 299,259 (36.5%), 99,163 with MetALD (12.1%), and 38,552 (4.7%) with ALD. The NLP algorithm had a high correlation with steatosis on chart review, with a κ of 0.86 (95% CI 0.82–0.90), sensitivity of 0.96, and specificity of 0.90. Classification of MASLD, MetALD, ALD, and no SLD by the algorithm also showed high correlation with chart review, with a κ of 0.87 (95% CI 0.82–0.91). This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using I nternational Classification of D iseases-9/10 codes. DISCUSSION: An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration.
- Open Access
- 11 September 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 14 (1) , 123-130
Health Insurance Coverage Mandates: Colorectal Cancer Screening in the Post-ACA Era
Building a culture of precision public health requires research that includes health delivery model with innovative systems, health policies, and programs that support this vision. Health insurance mandates are effective mechanisms that many state policymakers use to increase the utilization of preventive health services, such as colorectal cancer screening. This study estimated the effects of health insurance mandate variations on colorectal cancer screening post Affordable Care Act (ACA) era. The study analyzed secondary data from the Behavioral Risk Factor Surveillance System (BRFSS) and the NCI State Cancer Legislative Database (SCLD) from 1997 to 2014. BRFSS data were merged with SCLD data by state ID. The target population was U.S. adults, age 50 to 74, who lived in states where health insurance was mandated or nonmandated before and after the implementation of ACA. Using a difference-in-differences (DD) approach with a time-series analysis, we evaluated the effects of health insurance mandates on colorectal cancer screening status based on U.S. Preventive Services Task Force guidelines. The adjusted average marginal effects from the DD model indicate that health insurance mandates increased the probability of up-to-date screenings versus noncompliance by 2.8% points, suggesting that an estimated 2.37 million additional age-eligible persons would receive a screening with such health insurance mandates. Compliant participants' mean age was 65 years and 57% were women (n = 32,569). Our findings are robust for various model specifications. Health insurance mandates that lower out-of-pocket expenses constitute an effective approach to increase colorectal cancer screenings for the population, as a whole. Prevention Relevance: The value added includes future health care reforms that increase access to preventive services, such as CRC screening, are likely with lower out-of-pocket costs and will increase the number of people who are considered “up-to-date”. Such policies have been used historically to improve health outcomes, and they are currently being used as public health strategies to increase access to preventive health services in an effort to improve the nation's health.
- 11 September 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 14 (1) , 123-130
Open AccessHealth Insurance Coverage Mandates: Colorectal Cancer Screening in the Post-ACA Era
Building a culture of precision public health requires research that includes health delivery model with innovative systems, health policies, and programs that support this vision. Health insurance mandates are effective mechanisms that many state policymakers use to increase the utilization of preventive health services, such as colorectal cancer screening. This study estimated the effects of health insurance mandate variations on colorectal cancer screening post Affordable Care Act (ACA) era. The study analyzed secondary data from the Behavioral Risk Factor Surveillance System (BRFSS) and the NCI State Cancer Legislative Database (SCLD) from 1997 to 2014. BRFSS data were merged with SCLD data by state ID. The target population was U.S. adults, age 50 to 74, who lived in states where health insurance was mandated or nonmandated before and after the implementation of ACA. Using a difference-in-differences (DD) approach with a time-series analysis, we evaluated the effects of health insurance mandates on colorectal cancer screening status based on U.S. Preventive Services Task Force guidelines. The adjusted average marginal effects from the DD model indicate that health insurance mandates increased the probability of up-to-date screenings versus noncompliance by 2.8% points, suggesting that an estimated 2.37 million additional age-eligible persons would receive a screening with such health insurance mandates. Compliant participants' mean age was 65 years and 57% were women (n = 32,569). Our findings are robust for various model specifications. Health insurance mandates that lower out-of-pocket expenses constitute an effective approach to increase colorectal cancer screenings for the population, as a whole. Prevention Relevance: The value added includes future health care reforms that increase access to preventive services, such as CRC screening, are likely with lower out-of-pocket costs and will increase the number of people who are considered “up-to-date”. Such policies have been used historically to improve health outcomes, and they are currently being used as public health strategies to increase access to preventive health services in an effort to improve the nation's health.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e18629
The impact of Massachusetts health reform on breast cancer surgery.
E18629Background: There are substantial disparities in breast cancer treatment by insurance and socioeconomic status. Women with private insurance are more likely to undergo reconstruction post-mastectomy than Medicaid-insured or the uninsured. Private insurance is also associated with higher rates of breast-conserving therapy. Insurance coverage expansions provide a natural experiment for studying the relationship between insurance availability and patterns of care. Methods: We employ a quasi-experimental framework to assess the effects of Massachusetts Health Reform on whether women undergoing surgery for breast cancer receive breast conserving surgery (BCS) and whether those receiving mastectomy undergo reconstruction. Data come from the Massachusetts Cancer Registry and the Surveillance Epidemiology and End Results (SEER) cancer registries for 2001-2013. We exploit variation across states and age groups to estimate the relationship between health reform and type of BCA surgery within a difference-in-d...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e18629
The impact of Massachusetts health reform on breast cancer surgery.
E18629Background: There are substantial disparities in breast cancer treatment by insurance and socioeconomic status. Women with private insurance are more likely to undergo reconstruction post-mastectomy than Medicaid-insured or the uninsured. Private insurance is also associated with higher rates of breast-conserving therapy. Insurance coverage expansions provide a natural experiment for studying the relationship between insurance availability and patterns of care. Methods: We employ a quasi-experimental framework to assess the effects of Massachusetts Health Reform on whether women undergoing surgery for breast cancer receive breast conserving surgery (BCS) and whether those receiving mastectomy undergo reconstruction. Data come from the Massachusetts Cancer Registry and the Surveillance Epidemiology and End Results (SEER) cancer registries for 2001-2013. We exploit variation across states and age groups to estimate the relationship between health reform and type of BCA surgery within a difference-in-d...